Amoy Diagnostics is a technology company.
Amoy Diagnostics has raised $11.0M across 1 funding round.
Amoy Diagnostics has raised $11.0M in total across 1 funding round.
Amoy Diagnostics has raised $11.0M in total across 1 funding round.
Amoy Diagnostics's investors include Qiming Venture Partners.
Amoy Diagnostics (AmoyDx) is a diagnostics company specializing in precision oncology tools, developing NGS-based and PCR-based assays for cancer detection and companion diagnostics. It serves oncology labs, hospitals, and clinicians worldwide, solving the problem of accurate, accessible molecular testing for personalized cancer treatments like lung cancer therapies.[2][3][1] Key products include the proprietary HANDLE NGS technology for rapid library preparation and ddCapture for sensitive variant detection in FFPE and liquid biopsies, alongside PCR panels approved as companion diagnostics in Japan for drugs like Taletrectinib and Lorlatinib.[1][3][4] The company shows strong growth through regulatory approvals and commercial launches, such as the HANDLE OncoPro Panels.[4]
Founded by Dr. Xiaoming Zhang, Amoy Diagnostics emerged with a focus on advancing molecular diagnostics in oncology.[5] Zhang's vision drove the creation of innovative cancer assays, starting from its base in China and expanding globally.[5][2] Early traction came through proprietary technologies like ADx-ARMS PCR and HANDLE NGS, evolving into a portfolio of companion diagnostics amid rising demand for precision medicine.[1][4] Pivotal moments include recent Japanese approvals for its Pan Lung Cancer PCR Panel as a primary companion diagnostic for multiple therapies, marking international expansion.[3]
AmoyDx rides the precision oncology wave, where NGS and PCR diagnostics enable targeted therapies amid rising cancer incidence and immunotherapy adoption.[2][3] Timing aligns with global regulatory pushes for companion diagnostics, as seen in Japan approvals for lung cancer drugs, amid market forces like aging populations and demand for liquid biopsies.[3][1] It influences the ecosystem by breaking access barriers, fostering partnerships, and standardizing high-sensitivity testing to accelerate personalized care worldwide.[2]
AmoyDx is poised for expansion with more HANDLE panel launches and additional regulatory nods, capitalizing on NGS accessibility trends and AI-enhanced analysis.[1][4] Emerging forces like multi-omics integration and global equity initiatives will shape its path, potentially amplifying influence through broader companion diagnostic adoption. As a leader in oncology diagnostics, it reinforces the shift toward equitable precision medicine, building on its barrier-breaking foundation.[2]
Amoy Diagnostics has raised $11.0M across 1 funding round. Most recently, it raised $11.0M Series A in January 2015.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jan 1, 2015 | $11.0M Series A | Qiming Venture Partners |